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Chronic viral hepatitis B and C are important global causes of morbidity because of liver disease. Fortunately, diagnostic markers for both these diseases are now available and facilitate the selection of patients for treatment, and monitoring of this. Newer tools should improve our understanding of the mechanism of viral persistence in patients with chronic hepatitis and the pathogenesis of these diseases.
Hepatitis B Hepatitis B is caused by the hepatitis B virus (HBV), a 42 nm, enveloped DNA virus. The virus possesses an outer envelope, expressing hepatitis B surface antigen (HBsAg), and an inner nucleocapsid, expressing hepatitis B core antigen (HBcAg) and hepatitis B e antigen (HBeAg). The genome of HBV is a small, circular double-stranded DNA of about 3200 bases.' HBsAg consists of three envelope proteins (pre-S 1, pre-S2, and S), which originate from one gene. The two nucleocapsid proteins, HBcAg and HBeAg, are the products of a single gene region on the viral genome,2 which has two initiation codons. Initiation of translation at the first site (nucleotide 1814) produces a 312 amino acid polypeptide (P25). With subsequent processing, the resultant polypeptide is secreted as HBeAg (P15-18). Translation from the second initiation codon (nucleotide 1901) results in unprocessed core polypeptides which are assembled into HBcAg particles.
The pathogenesis of the disease is incompletely understood. Immunological mechanisms seem important, since most evidence suggests that HBV is not usually cytopathic, and that the expression of disease involves a poorly understood interplay between viral and host factors over time.
DIAGNOSIS OF HEPATITIS B: IMPLICATIONS FOR TREATMENT
Serological markers for clinical diagnosis of HBV infection have been well characterised, and are now complemented by newer molecular biological techniques. The most widely used test for diagnosis of HBV is an assay for HBsAg. Current immunoassays for HBsAg detect 100-200 pg HBsAg per ml of serum, corresponding to roughly 3 X 107 particles per ml. Most HBeAg positive carriers have more than 105 genomes per ml serum. Immunity after infection with HBV is characterised by the presence of anti-HBs and anti-HBc antibodies in serum. Immunity after vaccination is characterised by the presence of anti-HBs.
ASSAY OF HBV-DNA
The dot blot hybridisation test for serum HBV-DNA correlates with infectivity and is an important means of determining both the presence of viral genomes and the response to antiviral treatment. Amounts of HBV-DNA are expressed in pg per ml or, alternatively, genome equivalents per ml. One pg corresponds to 2-86X 105 genome equivalents. The usual range of sensitivity is 0 1-1 pg or 10' genome equivalents per ml of serum. At least 1035 virions have to be present in a specimen to be detected by dot blot assay. Liquid phase hybridisation assays for HBV-DNA have also been developed, in which extracted HBV-DNA is mixed with '25I-labelled nucleic acid probe and allowed to hybridise, then free and hybridised probe is separated by column chromatography. Chemoluminescent assays are under investigation.
Southern blot assay is most useful in the study of liver DNA samples, allowing detection of integrated or free episomal HBV-DNA.4
POLYMERASE CHAIN REACTION FOR HBV-DNA Polymerase chain reaction (PCR) permits the detection, cloning and sequencing of HBV genomes from patients with low level hepatitis B viraemia. It is at least 1 O times more sensitive than dot blot hybridisation assays for HBV. In practice, 3 X 10 6 pg cloned HBV can be detected by ethidium bromide staining after 50 cyles of PCR.5 By using a nested primer technique, the sensitivity and specificity of the test is improved (1 molecule per 106 cells), and the amplified product can be visualised in a same day test. The sensitivity can also be improved to detection of less than 1 fg (100 ag) of original DNA if the amplified DNA is hybridised to labelled probe and detected by autoradiography. Contamination remains the major difficulty of the procedure.
ACUTE HEPATITIS B: DIAGNOSIS
HBsAg is the first marker to appear in serum, followed by HBV-DNA, HBeAg and DNA polymerase, and anti-HBC. 6 Interferon alfa treatment is indicated in patients with chronic hepatitis B who are HBsAg-positive, HBV-DNA negative and/or HBeAg-positive, and who have increased serum activities of alanine and aspartate aminotransferase (at least twice the upper limit of normal). Patients who are positive for HBsAg but negative for HBeAg and HBV-DNA should not be treated. Liver biopsies are advised in order to confirm the diagnosis and to stage the disease. The immediate goal of treatment is to eradicate viral replication and ameliorate the underlying disease. Responses to interferon alfa are characterised by a loss of HBV-DNA and HBeAg from serum, a fall in serum aminotransferase activities to within the normal range, and subsequent improvement in liver histology. In some individuals, HBsAg is also cleared, followed by the appearance of anti-HBs. A typical pattern of response is shown in Fig 1 It has been suggested that the presence of circulating pre-core mutants could predict which patients would respond favourably or otherwise to interferon alfa. To address this, we analysed data from 15 patients with chronic hepatitis B who were treated with interferon (nine responders and six non-responders). Serum samples were collected before and after treatment. Circulating HBeAg negative mutants were not found before treatment in either responders or non-responders. These results suggest that a predominance of HBeAg negative virions cannot be considered the overriding factor in patients who respond to treatment. 14 Non responders represent a difficult problem in management. The use of a short course of prednisolone before interferon treatment has been advocated, but in prospective studies this has not led to higher response rates, except perhaps in those patients who have relatively inactive disease. Interferon may be used to treat anti-HBe positive, HBV-DNA positive patients, but many tend to relapse after stopping interferon. Anti-HBe and HBV-DNA positive patients with compensated cirrhosis but raised serum transaminase activities may be amenable to treatment with a lower dose (1 to 3 MU three times weekly) for a year. These patients may have lower serum concentrations of HBV-DNA (50 pg/ml) and may lose HBV-DNA with improvement in serum aminotransferases.'7-' Many of these patients have hypersplenism, however, and their thrombocytopenia and leukopenia require at least weekly monitoring. They are at greater risk of infections, and relapses also occur in these patients. Responses may be better in younger patients without cirrhosis compared with older patients and those with cirrhosis.
Other groups of patients who present difficult problems include Chinese patients, patients with advanced cirrhosis, and patients with other major illnesses who are immunosuppressed. Chinese patients and children with active disease and high ALT values probably respond to interferon, or pulsed corticosteroid treatment and interferon, in a similar manner to other adults. 20 Patients with advanced cirrhosis may decompensate with interferon and should not be treated.
MARKERS OF HBV AND LIVER TRANSPLANTATION
Reinfection of the grafted liver and development of chronic hepatitis is the major shortcoming of liver transplant for cirrhosis caused by HBV Hepatitis C Acute infection with hepatitis C virus (HCV) may either be severe or asymptomatic and unnoticed. The acute disease may resolve completely, but has a disturbing propensity to lead to chronic hepatitis C, explaining the relatively high prevalence of the disease. Chronic HCV infection may lead to mild illness only, which may be asymptomatic for decades and not progressive. A carrier state is recognised in patients who are HCV-RNA positive but have normal ALT values. In others, the disease is inexorably progressive, and persistent life long infection leads progressively to chronic active hepatitis, cirrhosis, portal hypertension, and even hepatocellular carcinoma.
Sensitive and specific markers for identification of HCV infection are now available. However, the HCV markers used in diagnosis still rely on recombinantly cloned antigens, and in some circumstances the diagnosis remains difficult. shown to be associated with chronic infections and correlated with infectivity in blood donations.45A8
When screening low risk groups such as blood donors, however, false-positive results were common. False-positive results were also common in patients with hypergammaglobulinaemia, and in stored tropical samples.49 50 The assay also lacked sensitivity.
Second generation ELISAs which incorporate two extra HCV derived recombinant proteins have increased the sensitivity of the assay.5'-53 Antibodies to c22c are an earlier finding and occur more frequently than those to c100-3 during the course of HCV infection. A protein derived from the NS3 and NS4 regions (c200), or a smaller fragment of it (c33c) from NS3 alone, is also included in the second generation assays. The c200 protein is the product of a large cloned fragment, combining both the c33c and c100-3 regions. The detection of antibodies to the El and E2/NS 1 glycoproteins has proven elusive, probably because of the sequence heterogeneity found in these regions. Antibodies to envelope proteins have been detected in viraemic patients, and it is therefore uncertain whether these antibodies are neutralising.5s57 IgM responses to HCV c100-3 antigen have been investigated in acute and chronic disease. Detectable levels have been found as early as four weeks after inoculation but can last for up to two years in individuals with chronic infection.58 59 Anti-HCV IgM is usually present in patients with raised ALT activities. The test is of uncertain importance at present, but may have some predictive value regarding progression to chronicity, and response to antiviral treatment.
SUPPLEMENTARY TESTS FOR ANTIBODY TO HCV
The most widely used method for supplementary testing is the recombinant immunoblot assay (RIBA) (Chiron Corporation) in which antibodies are sought to recombinant antigens of HCV coated on nitrocellulose strips. The second generation test (RIBA-4) includes bands 5-1-1, clOO-3, c22-3, and c33c. Samples are regarded as confirmed positive if antibodies to two or more of the HCV proteins are present and indeterminate if antibody to only one antigen is found. The value of RIBA in excluding false-positive results has been extensively shown, as has a correlation between RIBA positivity and viraemia.6061
The utility of synthetic peptides as antigens in the immunodiagnosis of HIV infection has led to the production of similar peptides using the deduced amino acid sequence of HCV. DETECTION The average time from transfusion to seroconversion is of the order of seven to eight weeks with the second generation tests; antic33 or anti-c22 antibodies often appear a week or two earlier than anti-clOO-3. Seroconversion occurs much less frequently, and in lower titre, in acute self limiting infections compared with those that progress to become chronic.4' 83 Serological testing now indicates that seroconversion to anti-HCV occurs in 85-100% of patients with chronic blood transfusion associated NANB hepatitis.46 A proportion of patients with transfusion associated and sporadically acquired NANB hepatitis remain anti-HCV seronegative, however. It will be important to define whether this represents HCV infection with poor serological response, or whether it is the result of other, as yet unclassified, NANB agents.
The acute disease may resolve completely with clearance of HCV-RNA from serum. A suitable immunodiagnostic test for resolved infection and immunity is not available, but antibodies to the envelope region are being sought.
In some patients, a very early appearance of anti-HCV may be the result of passively acquired antibody from the donor blood.
Serum HCV-RNA has been detected within one to three weeks of blood transfusion in patients with HCV; it usually lasts less than four months in patients with acute self limited HCV infection, but may persist for decades in patients with chronic disease. 68 Anti-HCV can persist for years, and even decades, in chronic hepatitis C but may decline in titre or disappear with resolution. A small percentage of patients seem to eradicate HCV-RNA permanently after chronic infection but this is usually seen in less than 5-10o/o. 41 47 HCV-RNA usually persists in patients with abnormal serum aminotransferase activities and anti-HCV antibodies. Although most patients with raised serum ALT are HCV-RNA positive, the converse is not always true.
Isolates of HCV-RNA in individual patients may show nucleotide substitutions with time, suggesting that the HCV-RNA mutates at a rate similar to that of other RNA viruses. 89 The emergence of a mutant population does not always correlate with peaks in ALT.
It is not easy to project the prognosis for patients seen at one point in time. Episodes of hepatic necrosis may progress at variable rates to cirrhosis and, conversely, the lesion may revert in some patients to inactive hepatitis. Cirrhosis may develop in patients with an initially mild histological pattern; the mechanism for this transition is not known but may occur after repeated attacks of lobular necrosis associated with piecemeal necrosis. A relation between histological exacerbations and episodic clinical course is not proved, however.
The morphological features of cirrhosis caused by HCV are not specific to the disease; in the earlier stages, lymphoid aggregates may be seen.
AUTOIMMUNE HEPATITIS AND HEPATITIS C
There are conflicting reports regarding the occurrence of HCV antibodies in patients with autoimmune liver disease. Clearly, the ELISA for anti-HCV is prone to false-positive results in patients with high concentrations of immunoglobulins in serum.50 These falsereactive anti-HCV antibodies in patients with anti-smooth muscle antibody (anti-SMA) may actually disappear with immunosuppressive treatment, as immunoglobulin levels decrease.90 However, Italian patients with autoimmune chronic active hepatitis seem to have a high frequency of genuine exposure to HCV, whereas seropositivity in English patients usually represents a false-positive result. It is therefore not certain whether anti-HCV in patients with chronic active hepatitis represents persistent anti-HCV from earlier disease, whether the autoimmune disease is induced by HCV,`' or whether autoantibodies in autoimmune hepatitis patients cross react with HCV related antigens.92 In Japan, 80% of patients with chronic NANB hepatitis have circulating antibodies to a pentadecapeptide (Gor), an epitope of normal hepatocytes; this phenomenon may represent an autoimmune response peculiar to type C hepatitis. 93 Up to 50%/o of patients with type II autoimmune hepatitis (anti-liver kidney microsomal (LKM) antibody positive) are anti-HCV positive, and anti-HCV and anti-LKM in association may also represent another example of molecular mimicry. Anti 
, and have lower titres of anti-LKM than patients without anti-HCV. The target antigen of antibodies to LKM is a portion of the cytochrome P450 II D6 molecule; anti-LKM is not directed to a c100-3 epitope but some sequence homology between HCV and cytochrome P450 may exist.94 This association has some therapeutic implications, as the autoimmune disease is responsive to corticosteroids, and may be aggravated by interferon alfa. It is preferable to confirm HCV viraemia in these patients by PCR.
TREATMENT OF ACUTE HEPATITIS C
The management of acute sporadic or transfusion related hepatitis C is along conventional lines, and is largely non-specific and supportive. The diagnosis remains one of exclusion in most patients, although if the patient is seen early enough, HCV-RNA in serum may be detectable at the time that serum aminotransferases are high. Anti-HCV may be detectable, particularly in severe, icteric cases, and in most of those patients destined to go on to chronic disease. Many patients will not be jaundiced. Approximately 50% of patients will still have raised serum aminotransferase activities six months after diagnosis. Therapeutic trials of interferon alfa have been undertaken. In general, these have been relatively small trials, and interferon has usually been administered for 12 weeks. A high proportion of patients (75%) have normal ALT at the end of treatment. This remission is not sustained when treatment is stopped, however, and the results do not differ significantly from untreated patients. Most have not reduced the rate of chronic disease, but might indicate an amelioration of the severity of the chronic hepatitis lesion. A Japanese trial of interferon beta, given intravenously for one to three months, did significantly reduce the risk of chronic hepatitis.95 Until these findings can be reproduced, however, the routine administration of interferon for acute hepatitis C cannot be advised. Perhaps a longer course of treatment (six months to one year) may be beneficial. TREATMENT The most important predictive factors of response to interferon are absence of cirrhosis, younger age, HCV-RNA value, and possibly viral genotype.
RIBAVIRIN
Ribavirin is a synthetic nucleotide, a guanosine analogue, which possesses a broad spectrum of activity against both DNA and RNA viruses in vitro and in vivo.'05 Its efficacy has been shown in several viral diseases. The drug exerts its action after intracellular phosphorylation to mono-, di-, and triphosphate nucleotides. The precise mode of action probably includes perturbation of intracellular nucleoside triphosphate pools, interference with the formation of the 5' cap structure of viral mRNA by competitive inhibition of both guanyltransferase capping enzymes and methyltransferase capping enzymes, direct inhibition of the viral mRNA polymerase complex, and possibly enhancement of macrophage inhibition of viral replication.
The pharmacokinetics of ribavirin have been studied. The bioavailability of oral formulations has been calculated at 19-65% (compared with intravenous administration). The distribution half life is one to three hours, but the terminal half-life is prolonged (27-52 hours), perhaps because of sequestration within red cells and other tissues. Ribavirin is concentrated 10-50 fold serum levels in red blood cells, and crosses the blood-brain barrier. Peak plasma concentrations range from 5-13 jM after single oral doses of 600-2400 mg. The excretion of the drug is predominantly renal.
The major side effects of the drug that have been reported include anaemia, a metallic taste, dry mouth, flatulence, dyspepsia, nausea, headaches, irritability, emotional lability, fatigue, insomnia, skin rashes, and myalgia. Mild reversible anaemia is common. Modest increases in uric acid have been reported.
STUDIES OF RIBAVIRIN IN HCV INFECTION
In an unpublished study, Tong treated 22 patients with chronic hepatitis NANB with ribavirin 1200 mg daily for four weeks. Serum ALT and AST activities declined from a median of 145 to 78 and 86 to 52 IU/1, respectively. After four to eight weeks' follow up, median values of both ALT and AST had increased to those before treatment. An openlabel study in Sweden, in which ribavirin was prescribed to 10 patients with chronic hepatitis C (1000-1200 mg/day) for 12 weeks, has been completed. Median serum AST values declined, but rose to values before treatment after the end of therapy. 104 A small study from the National Institutes of Health using escalating doses of ribavirin (600-1200 mg) showed a somewhat slower fall in serum aminotransferases, perhaps reflecting the lower starting dose of ribavirin.106 There was a significant decrease in geometric mean titres of HCV-RNA. At the Royal Free Hospital, we have treated 15 patients with chronic hepatitis C with ribavirin. Seven patients (46%) had a 50% or greater decline in serum aminotransferase activity. Responsive patients may have negative serum HCV-RNA, but those with a lesser decline in ALT tend to remain positive. Ribavirin may have a role in patients with cirrhosis and leukopenia, or those with autoimmune disease and hepatitis C. Further controlled trials to assess response and relapse rates are warranted, and a multicentre, placebo controlled trial of ribavirin for hepatitis C is now in progress. Studies of ribavirin and interferon alfa used together are also indicated.
